TY - JOUR
T1 - Decoding the historical tale
T2 - COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
AU - EPICOVIDEHA registry
AU - Salmanton-García, Jon
AU - Marchesi, Francesco
AU - Farina, Francesca
AU - Weinbergerová, Barbora
AU - Itri, Federico
AU - Dávila-Valls, Julio
AU - Martín-Pérez, Sonia
AU - Glenthøj, Andreas
AU - Hersby, Ditte Stampe
AU - Gomes da Silva, Maria
AU - Nunes Rodrigues, Raquel
AU - López-García, Alberto
AU - Córdoba, Raúl
AU - Bilgin, Yavuz M.
AU - Falces-Romero, Iker
AU - El-Ashwah, Shaimaa
AU - Emarah, Ziad
AU - Besson, Caroline
AU - Kohn, Milena
AU - Van Doesum, Jaap
AU - Ammatuna, Emanuele
AU - Marchetti, Monia
AU - Labrador, Jorge
AU - Zambrotta, Giovanni Paolo Maria
AU - Verga, Luisa
AU - Jaksic, Ozren
AU - Nucci, Marcio
AU - Piukovics, Klára
AU - Cabirta-Touzón, Alba
AU - Jiménez, Moraima
AU - Arellano, Elena
AU - Espigado, Ildefonso
AU - Blennow, Ola
AU - Nordlander, Anna
AU - Meers, Stef
AU - van Praet, Jens
AU - Aiello, Tommaso Francesco
AU - Garcia-Vidal, Carolina
AU - Fracchiolla, Nicola
AU - Sciumè, Mariarita
AU - Seval, Guldane Cengiz
AU - Žák, Pavel
AU - Buquicchio, Caterina
AU - Tascini, Carlo
AU - Gräfe, Stefanie K.
AU - Schönlein, Martin
AU - Adžić-Vukičević, Tatjana
AU - Bonuomo, Valentina
AU - Cattaneo, Chiara
AU - Nizamuddin, Summiya
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/5
Y1 - 2024/5
N2 - Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. Methods: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Findings: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. Interpretation: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases. Funding: Not applicable.
AB - Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced. Methods: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020–2022). Findings: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival. Interpretation: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases. Funding: Not applicable.
KW - COVID-19
KW - Haematological malignancy
KW - ICU
KW - Immunosuppression
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85188194524&partnerID=8YFLogxK
U2 - 10.1016/j.eclinm.2024.102553
DO - 10.1016/j.eclinm.2024.102553
M3 - Article
AN - SCOPUS:85188194524
SN - 2589-5370
VL - 71
JO - EClinicalMedicine
JF - EClinicalMedicine
M1 - 102553
ER -